Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers

Verified by: National Institute on Drug Abuse (NIDA), May 2008
First Received: May 23, 2008 | Last Updated: May 23, 2008 | Phase: Phase 4 | Start Date: August 2002
Overall Status: Completed | Estimated Enrollment: 463
  • …
  • Tell a FriendPrint

Purpose of the project is to examine the effectiveness of Reinforcement-Based Treatment (RBT) on drug abuse and psychosocial outcomes of iner city opiate abusers who have recently completed a brief detoxification...

Brief Summary

Official Title: “Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers”

Purpose of the project is to examine the effectiveness of Reinforcement-Based Treatment (RBT) on drug abuse and psychosocial outcomes of iner city opiate abusers who have recently completed a brief detoxification.

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
  • Study Primary Completion Date: February 2007

Detailed Clinical Trial Description

Participants are randomized into one of 3-groups: 1) those receiving intensive behavioral therapy plus abstinence-contingent housing, 2) those receiving recovery housing alone, and 3) those receiving standard care (referrals to community providers). For the two groups receiving recovery housing, rent payment is provided for a period of 3 months, as long as the participant remains drug-free.

Intervention(s) in this Clinical Trial

  • Behavioral: Reinforcement-Based Treatment
    • 3 group random assignment to receive, standard care, recovery housing alone, or recovery housing plus behavioral treatment

Arms, Groups and Cohorts in this Clinical Trial

  • No Intervention: 1
    • Standard care following detoxification
  • Active Comparator: 2
    • Recovery housing following detoxification
  • Experimental: 3
    • Recovery housing plus counseling

Outcome Measures for this Clinical Trial

Primary Measures

  • Drug abstinence at follow-up
    • Time Frame: 1, 3 and 6 months
      Safety Issue?: No

Secondary Measures

  • Rates of employment
    • Time Frame: 1, 3, and 6 months
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • opiate dependent agree to live in recovery housing

Exclusion Criteria:

  • acute psychiatric disorder pregnant over 65

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 65 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers

Clinical Trial Investigator Information

Lead Investigator: National Institute on Drug Abuse (NIDA) NIH

Overall Clinical Trial Officials and Contacts

Maxine Stitzer, Ph.D. Principal Investigator Johns Hopkins University  

Additional Information

Information obtained from ClinicalTrials.gov on February 09, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00685620

Study ID Number: BPR010213-01

ClinicalTrials.gov Identifier: NCT00685620

Health Authority: United States: Federal Government

  • …
  • Tell a FriendPrint

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00685620